MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*”Architects”: Geriatrics, Gerontology, Geroscience, Longevity, Healthspan & Aging
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO)
Organization & Developments: Telomir Pharmaceuticals
Parents
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO)
Children
*Lead candidate is TELOMIR-1, and the company believes it has the potential to act as an Interleukin-17 inhibitor, which may play a role in age-related inflammatory conditions including "hemochromatosis and osteoarthritis as well as in post-chemotherapy health problems."
*The company is a pre-clinical stage biopharma developing treatment candidates for inflammatory disease conditions.
2023: IPO Update: Telomir Pharmaceuticals Proposes IPO Terms_seekingalpha.com
2024: Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
Jumps
Finance & Acquisitions: Telomir Pharmaceuticals
Key People: Telomir Pharmaceuticals